Emerging Technologies for the Treatment of COVID-19.
Biotechnology
COVID-19
Coronavirus
SARS-CoV-2
Treatment
Journal
Advances in experimental medicine and biology
ISSN: 0065-2598
Titre abrégé: Adv Exp Med Biol
Pays: United States
ID NLM: 0121103
Informations de publication
Date de publication:
2021
2021
Historique:
entrez:
3
3
2021
pubmed:
4
3
2021
medline:
6
3
2021
Statut:
ppublish
Résumé
The new coronavirus, named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), turned into a pandemic affecting more than 200 countries. Due to the high rate of transmission and mortality, finding specific and effective treatment options for this infection is currently of urgent importance. Emerging technologies have created a promising platform for developing novel treatment options for various viral diseases such as the SARS-CoV-2 virus. Here, we have described potential novel therapeutic options based on the structure and pathophysiological mechanism of the SARS-CoV-2 virus, as well as the results of previous studies on similar viruses such as SARS and MERS. Many of these approaches can be used for controlling viral infection by reducing the viral damage or by increasing the potency of the host response. Owing to their high sensitivity, specificity, and reproducibility, siRNAs, aptamers, nanobodies, neutralizing antibodies, and different types of peptides can be used for interference with viral replication or for blocking internalization. Receptor agonists and interferon-inducing agents are also potential options to balance and enhance the innate immune response against SARS-CoV-2. Solid evidence on the efficacy and safety of such novel technologies is yet to be established although many well-designed clinical trials are underway to address these issues.
Identifiants
pubmed: 33656715
doi: 10.1007/978-3-030-59261-5_7
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
81-96Références
Chan JF, Kok KH, Zhu Z, Chu H, To KK, Yuan S et al (2020) Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg Microb Infect 9(1):221–236
doi: 10.1080/22221751.2020.1719902
Agostini ML, Andres EL, Sims AC, Graham RL, Sheahan TP, Lu X et al (2018) Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. MBio 9(2):e00221–e00218. https://doi.org/10.1128/mBio.00221-18
doi: 10.1128/mBio.00221-18
pubmed: 29511076
pmcid: 5844999
Brown AJ, Won JJ, Graham RL, Dinnon KH III, Sims AC, Feng JY et al (2019) Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase. Antivir Res 169:104541. https://doi.org/10.1016/j.antiviral.2019.104541
doi: 10.1016/j.antiviral.2019.104541
pubmed: 31233808
de Wit E, Feldmann F, Cronin J, Jordan R, Okumura A, Thomas T et al (2020) Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection. Proc Natl Acad Sci USA 117(12):6771–6776
pubmed: 32054787
doi: 10.1073/pnas.1922083117
Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M et al (2020) Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 30(3):269–271
pubmed: 32020029
pmcid: 32020029
doi: 10.1038/s41422-020-0282-0
Chu C, Cheng V, Hung I, Wong M, Chan K, Chan K et al (2004) Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax 59(3):252–256
pubmed: 14985565
pmcid: 1746980
doi: 10.1136/thorax.2003.012658
Fox R (1996) Anti-malarial drugs: possible mechanisms of action in autoimmune disease and prospects for drug development. Lupus 5(Suppl 1):4–10
doi: 10.1177/0961203396005001031
Gao J, Tian Z, Yang X (2020) Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends 14(1):72–73
pubmed: 32074550
doi: 10.5582/bst.2020.01047
Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P et al (2020) In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis Mar 9:ciaa237. https://doi.org/10.1093/cid/ciaa237 . Online ahead of print
doi: 10.1093/cid/ciaa237
Smith T, Prosser T (2020) COVID-19 drug therapy-potential options. https://www.lusiadas.pt/pt/Covid19%20Public%20Resource%20Center/Clinical%20and%20Research%20Articles/18032020/COVID-19-Drug-Therapy_Mar-2020.pdf
Arabi Y, Balkhy H, Hajeer AH, Bouchama A, Hayden FG, Al-Omari A et al (2015) Feasibility, safety, clinical, and laboratory effects of convalescent plasma therapy for patients with Middle East respiratory syndrome coronavirus infection: a study protocol. Springerplus 4:709. https://doi.org/10.1186/s40064-015-1490-9
doi: 10.1186/s40064-015-1490-9
pubmed: 26618098
pmcid: 4653124
Agami R (2002) RNAi and related mechanisms and their potential use for therapy. Curr Opin Chem Biol 6(6):829–834
pubmed: 12470738
doi: 10.1016/S1367-5931(02)00378-2
Cerutti H (2003) RNA interference: traveling in the cell and gaining functions? Trends Genet 19(1):39–46
pubmed: 12493247
doi: 10.1016/S0168-9525(02)00010-0
Bajan S, Hutvagner G (2020) RNA-based therapeutics: from antisense oligonucleotides to miRNAs. Cell 9(1):137. https://doi.org/10.3390/cells9010137
doi: 10.3390/cells9010137
Bitko V, Barik S (2007) Respiratory viral diseases: access to RNA interference therapy. Drug Discov Today Ther Strateg 4(4):273–276
pubmed: 19081824
doi: 10.1016/j.ddstr.2008.01.001
Wu CJ, Chan YL (2006) Antiviral applications of RNAi for coronavirus. Expert Opin Investig Drugs 15(2):89–97
pubmed: 16433589
pmcid: 7103689
doi: 10.1517/13543784.15.2.89
Gao Y, Sun L, Dong JX, Xingye X, Shu Y, Chen M et al (2006) Rapid identification of small interfering RNA that can effectively inhibit the replication of multiple influenza B virus strains. Antivir Ther 11(4):431–438
pubmed: 16856616
Ge Q, McManus MT, Nguyen T, Shen C, Sharp PA, Eisen HN et al (2003) RNA interference of influenza virus production by directly targeting mRNA for degradation and indirectly inhibiting all viral RNA transcription. Proc Natl Acad Sci U S A 100(5):2718–2723
pubmed: 12594334
pmcid: 151407
doi: 10.1073/pnas.0437841100
He ML, Zheng BJ, Chen Y, Wong KL, Huang JD, Lin MC et al (2006) Kinetics and synergistic effects of siRNAs targeting structural and replicase genes of SARS-associated coronavirus. FEBS Lett 580(10):2414–2420
pubmed: 16638566
pmcid: 7094648
doi: 10.1016/j.febslet.2006.03.066
He ML, Zheng B, Peng Y, Peiris JSM, Poon LLM, Yuen KY et al (2003) Inhibition of SARS-associated coronavirus infection and replication by RNA interference. JAMA 290(20):2665–2666
pubmed: 14645307
doi: 10.1001/jama.290.20.2665
Meng B, Lui YW, Meng S, Cao C, Hu Y (2006) Identification of effective siRNA blocking the expression of SARS viral envelope E and RDRP genes. Mol Biotechnol 33(2):141–148
pubmed: 16757801
pmcid: 7090727
doi: 10.1385/MB:33:2:141
Pyrc K, Bosch BJ, Berkhout B, Jebbink MF, Dijkman R, Rottier P et al (2006) Inhibition of human coronavirus NL63 infection at early stages of the replication cycle. Antimicrob Agents Chemother 50(6):2000–2008
pubmed: 16723558
pmcid: 1479111
doi: 10.1128/AAC.01598-05
Qin ZL, Zhao P, Zhang XL, Yu JG, Cao MM, Zhao LJ et al (2004) Silencing of SARS-CoV spike gene by small interfering RNA in HEK 293T cells. Biochem Biophys Res Commun 324(4):1186–1193
pubmed: 15504339
pmcid: 7092946
doi: 10.1016/j.bbrc.2004.09.180
Zhang Y, Li T, Fu L, Yu C, Li Y, Xu X et al (2004) Silencing SARS-CoV spike protein expression in cultured cells by RNA interference. FEBS Lett 560(1–3):141–146
pubmed: 14988013
pmcid: 7127813
doi: 10.1016/S0014-5793(04)00087-0
Ecker DM, Jones SD, Levine HL (2015) The therapeutic monoclonal antibody market. MAbs 7(1):9–14
pubmed: 25529996
doi: 10.4161/19420862.2015.989042
Fung TS, Liu DX (2019) Human coronavirus: host-pathogen interaction. Annu Rev Microbiol 73:529–557
pubmed: 31226023
doi: 10.1146/annurev-micro-020518-115759
Masters PS (2006) The molecular biology of coronaviruses. Adv Virus Res 66:193–292
pubmed: 16877062
pmcid: 7112330
doi: 10.1016/S0065-3527(06)66005-3
Lim YX, Ng YL, Tam JP, Liu DX (2016) Human coronaviruses: a review of virus-host interactions. Diseases 4(3):26. https://doi.org/10.3390/diseases4030026
doi: 10.3390/diseases4030026
pmcid: 5456285
pubmed: 5456285
Shanmugaraj B, Siriwattananon K, Wangkanont K, Phoolcharoen W (2020) Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19). Asian Pac J Allergy Immunol 38(1):10–18
pubmed: 32134278
Coughlin M, Lou G, Martinez O, Masterman SK, Olsen OA, Moksa AA et al (2007) Generation and characterization of human monoclonal neutralizing antibodies with distinct binding and sequence features against SARS coronavirus using XenoMouse. Virol 361(1):93–102
doi: 10.1016/j.virol.2006.09.029
Zhang C, Wu Z, Li JW, Zhao H, Wang GQ (2020) The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist tocilizumab may be the key to reduce the mortality. Int J Antimicrob Agents 55(5):105954. https://doi.org/10.1016/j.ijantimicag.2020.105954
doi: 10.1016/j.ijantimicag.2020.105954
pubmed: 32234467
pmcid: 7118634
Coomes EA, Haghbayan H (2020) Interleukin-6 in COVID-19: a systematic review and meta-analysis. medRxiv. https://doi.org/10.1101/2020.03.30.20048058
Shum KT, Zhou J, Rossi JJ (2013) Aptamer-based therapeutics: new approaches to combat human viral diseases. Pharmaceuticals (Basel) 6(12):1507–1542
doi: 10.3390/ph6121507
DeStefano JJ, Nair GR (2008) Novel aptamer inhibitors of human immunodeficiency virus reverse transcriptase. Oligonucleotides 18(2):133–144
pubmed: 18637731
pmcid: 2966829
doi: 10.1089/oli.2008.0103
Kim SJ, Kim MY, Lee JH, You JC, Jeong S (2002) Selection and stabilization of the RNA aptamers against the human immunodeficiency virus type-1 nucleocapsid protein. Biochem Biophys Res Commun 291(4):925–931
pubmed: 11866454
doi: 10.1006/bbrc.2002.6521
Kissel JD, Held DM, Hardy RW, Burke DH (2007) Single-stranded DNA aptamer RT1t49 inhibits RT polymerase and RNase H functions of HIV type 1, HIV type 2, and SIVCPZ RTs. AIDS Res Hum Retrovir 23(5):699–708
pubmed: 17530996
doi: 10.1089/aid.2006.0262
Watrin M, Von Pelchrzim F, Dausse E, Schroeder R, Toulmé JJ (2009) In vitro selection of RNA aptamers derived from a genomic human library against the TAR RNA element of HIV-1. Biochemistry 48(26):6278–6284
pubmed: 19496624
doi: 10.1021/bi802373d
Cheng C, Dong J, Yao L, Chen A, Jia R, Huan L et al (2008) Potent inhibition of human influenza H5N1 virus by oligonucleotides derived by SELEX. Biochem Biophys Res Commun 366(3):670–674
pubmed: 18078808
doi: 10.1016/j.bbrc.2007.11.183
Gopinath SCB, Sakamaki Y, Kawasaki K, Kumar PKR (2006) An efficient RNA aptamer against human influenza B virus hemagglutinin. J Biochem 139(5):837–846
pubmed: 16751591
doi: 10.1093/jb/mvj095
Park SY, Kim S, Yoon H, Kim KB, Kalme SS, Oh S et al (2011) Selection of an antiviral RNA aptamer against hemagglutinin of the subtype H5 avian influenza virus. Nucleic Acid Ther 21(6):395–402
pubmed: 22017542
doi: 10.1089/nat.2011.0321
Wongphatcharachai M, Wang P, Enomoto S, Webby RJ, Gramer MR, Amonsin A et al (2013) Neutralizing DNA aptamers against swine influenza H3N2 viruses. J Clin Microbiol 51(1):46–54
pubmed: 23077124
pmcid: 3536225
doi: 10.1128/JCM.02118-12
Jang KJ, Lee NR, Yeo WS, Jeong YJ, Kim DE (2008) Isolation of inhibitory RNA aptamers against severe acute respiratory syndrome (SARS) coronavirus NTPase/helicase. Biochem Biophys Res Commun 366(3):738–744
pubmed: 18082623
doi: 10.1016/j.bbrc.2007.12.020
Wandtke T, Wozniak J, Kopinski P (2015) Aptamers in diagnostics and treatment of viral infections. Viruses 7(2):751–780
pubmed: 25690797
pmcid: 4353915
doi: 10.3390/v7020751
Hamers-Casterman C, Atarhouch T, Muyldermans S, Robinson G, Hammers C, Songa EB et al (1993) Naturally occurring antibodies devoid of light chains. Nature 363(6428):446–448
pubmed: 8502296
doi: 10.1038/363446a0
Arbabi Ghahroudi M, Desmyter A, Wyns L, Hamers R, Muyldermans S (1997) Selection and identification of single domain antibody fragments from camel heavy-chain antibodies. FEBS Lett 414(3):521–526
pubmed: 9323027
doi: 10.1016/S0014-5793(97)01062-4
Bakherad H, Gargari SLM, Rasooli I, RajabiBazl M, Mohammadi M, Ebrahimizadeh W et al (2013) In vivo neutralization of botulinum neurotoxins serotype E with heavy-chain camelid antibodies (VHH). Mol Biotechnol 55(2):159–167
pubmed: 23666874
doi: 10.1007/s12033-013-9669-1
Ebrahimizadeh W, Gargari SM, Rajabibazl M, Ardekani LS, Zare H, Bakherad H (2013) Isolation and characterization of protective anti-LPS nanobody against V. cholerae O1 recognizing Inaba and Ogawa serotypes. Appl Microbiol Biotechnol 97(10):4457–4466
pubmed: 23135228
doi: 10.1007/s00253-012-4518-x
Harmsen M, De Haard H (2007) Properties, production, and applications of camelid single-domain antibody fragments. Appl Microbiol Biotechnol 77(1):13–22
pubmed: 17704915
pmcid: 2039825
doi: 10.1007/s00253-007-1142-2
Aghamolaei H, Gargari SLM, Rasaee MJ, Ghanei M (2017) Camelid variable fragments of heavy chain antibodies (Nanobody): its applications in research, diagnosis and therapy. Minerva Biotecnol 29(2):89–100
Vanlandschoot P, Stortelers C, Beirnaert E, Ibañez LI, Schepens B, Depla E et al (2011) Nanobodies®: new ammunition to battle viruses. Antivir Res 92(3):389–407
pubmed: 21939690
doi: 10.1016/j.antiviral.2011.09.002
Detalle L, Stohr T, Palomo C, Piedra PA, Gilbert BE, Mas V et al (2016) Generation and characterization of ALX-0171, a potent novel therapeutic nanobody for the treatment of respiratory syncytial virus infection. Antimicrob Agents Chemother 60(1):6–13
pubmed: 26438495
doi: 10.1128/AAC.01802-15
De Bruyn S, De Smedt T, Allosery K, Crabbe P, De Brabandere V, Detalle L et al (2015) ALX-0171: safety and therapeutic potential of an inhaled anti-RSV Nanobody. RDD Europe 1:37–48
Zhao G, He L, Sun S, Qiu H, Tai W, Chen J et al (2018) A novel nanobody targeting Middle East respiratory syndrome coronavirus (MERS-CoV) receptor-binding domain has potent cross-neutralizing activity and protective efficacy against MERS-CoV. J Virol 92(18):e00837–e00818
pubmed: 29950421
pmcid: 6146697
doi: 10.1128/JVI.00837-18
Marqus S, Pirogova E, Piva TJ (2017) Evaluation of the use of therapeutic peptides for cancer treatment. J Biomed Sci 24(1):21. https://doi.org/10.1186/s12929-017-0328-x
doi: 10.1186/s12929-017-0328-x
pubmed: 28320393
pmcid: 5359827
Guo JP, Petric M, Campbell W, McGeer PL (2004) SARS corona virus peptides recognized by antibodies in the sera of convalescent cases. Virol 324(2):251–256
doi: 10.1016/j.virol.2004.04.017
Bhattacharya M, Sharma AR, Patra P, Ghosh P, Sharma G, Patra BC et al (2020) Development of epitope-based peptide vaccine against novel coronavirus 2019 (SARS-COV-2): immunoinformatics approach. J Med Virol 92(6):618–631
pubmed: 32108359
doi: 10.1002/jmv.25736
Zheng BJ, Guan Y, Hez M, Sun H, Du L, Zheng Y et al (2005) Synthetic peptides outside the spike protein heptad repeat regions as potent inhibitors of SARS-associated coronavirus. Antivir Ther 10(3):393–403
pubmed: 15918330
Schneider SE, Bray BL, Mader CJ, Friedrich PE, Anderson MW, Taylor TS et al (2005) Development of HIV fusion inhibitors. J Pept Sci 11(11):744–753
pubmed: 16130177
doi: 10.1002/psc.703
Apaydın ÇB, Cesur N, Stevaert A, Naesens L, Cesur Z (2019) Synthesis and anti-coronavirus activity of a series of 1-thia-4-azaspiro [4.5] decan-3-one derivatives. Arch Pharm (Weinheim) 352(6):e1800330. https://doi.org/10.1002/ardp.201800330
doi: 10.1002/ardp.201800330
Barton C, Kouokam JC, Lasnik AB, Foreman O, Cambon A, Brock G et al (2014) Activity of and effect of subcutaneous treatment with the broad-spectrum antiviral lectin griffithsin in two laboratory rodent models. Antimicrob Agents Chemother 58(1):120–127
pubmed: 24145548
pmcid: 3910741
doi: 10.1128/AAC.01407-13
Dyall J, Coleman CM, Hart BJ, Venkataraman T, Holbrook MR, Kindrachuk J et al (2014) Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection. Antimicrob Agents Chemother 58(8):4885–4893
pubmed: 24841273
pmcid: 4136000
doi: 10.1128/AAC.03036-14
Ito K, Yotsuyanagi H, Sugiyama M, Yatsuhashi H, Karino Y, Takikawa Y et al (2016) Geographic distribution and characteristics of genotype A hepatitis B virus infection in acute and chronic hepatitis B patients in Japan. J Gastroenterol Hepatol 31(1):180–189
pubmed: 26110395
doi: 10.1111/jgh.13030
O'Keefe BR, Giomarelli B, Barnard DL, Shenoy SR, Chan PK, McMahon JB et al (2010) Broad-spectrum in vitro activity and in vivo efficacy of the antiviral protein griffithsin against emerging viruses of the family Coronaviridae. J Virol 84(5):2511–2521
pubmed: 20032190
doi: 10.1128/JVI.02322-09
Wang C, Hua C, Xia S, Li W, Lu L, Jiang S (2019) Combining a fusion inhibitory peptide targeting the MERS-CoV S2 protein HR1 domain and a neutralizing antibody specific for the S1 protein receptor-binding domain (RBD) showed potent synergism against pseudotyped MERS-CoV with or without mutations in RBD. Viruses 11(1):31. https://doi.org/10.3390/v11010031
doi: 10.3390/v11010031
pmcid: 6356712
pubmed: 6356712
Xia S, Yan L, Xu W, Agrawal AS, Algaissi A, Tseng CTK et al (2019) A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike. Sci Adv 5(4):eaav4580. https://doi.org/10.1126/sciadv.aav4580
doi: 10.1126/sciadv.aav4580
pubmed: 30989115
pmcid: 6457931
Xia S, Liu M, Wang C, Xu W, Lan Q, Feng S et al (2020) Inhibition of SARS-CoV-2 infection (previously 2019-nCoV) by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion. Cell Res 30(4):343–355
pubmed: 32231345
doi: 10.1038/s41422-020-0305-x
Wong SK, Li W, Moore MJ, Choe H, Farzan M (2004) A 193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensin-converting enzyme 2. J Biol Chem 279(5):3197–3201
pubmed: 14670965
doi: 10.1074/jbc.C300520200
Kruse RL (2020) Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China. F1000Res 9:72. https://doi.org/10.12688/f1000research.22211.2
doi: 10.12688/f1000research.22211.2
pubmed: 32117569
pmcid: 7029759
Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA et al (2003) Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 426(6965):450–454
pubmed: 14647384
pmcid: 7095016
doi: 10.1038/nature02145
Monteil V, Kwon H, Prado P, Hagelkrüys A, Wimmer RA, Stahl M et al (2020) Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2. Cell 181(4):905–913
pubmed: 32333836
pmcid: 7181998
doi: 10.1016/j.cell.2020.04.004
Mustafa S, Balkhy H, Gabere MN (2018) Current treatment options and the role of peptides as potential therapeutic components for Middle East Respiratory Syndrome (MERS): a review. J Infect Public Health 11(1):9–17
pubmed: 28864360
doi: 10.1016/j.jiph.2017.08.009
Moghaddam MM, Aghamollaei H, Kooshki H, Barjini KA, Mirnejad R, Choopani A (2015) The development of antimicrobial peptides as an approach to prevention of antibiotic resistance. Rev Med Microbiol 26(3):98–110
doi: 10.1097/MRM.0000000000000032
Heiat M, Aghamollaei H, Moghaddam MM, Kooshki H (2014) Using CM11 peptide as a cell permeable agent for the improvement of conventional plasmid transformation methods in Escherichia coli and Bacillus subtilis. Minerva Biotecnol 26:149–157
Kaspar AA, Reichert JM (2013) Future directions for peptide therapeutics development. Drug Discov Today 18(17–18):807–817
pubmed: 23726889
doi: 10.1016/j.drudis.2013.05.011
Koehler JW, Smith JM, Ripoll DR, Spik KW, Taylor SL, Badger CV et al (2013) A fusion-inhibiting peptide against Rift Valley fever virus inhibits multiple, diverse viruses. PLoS Negl Trop Dis 7(9):e2430. https://doi.org/10.1371/journal.pntd.0002430
doi: 10.1371/journal.pntd.0002430
pubmed: 24069485
pmcid: 3772029
Vigant F, Santos NC, Lee B (2015) Broad-spectrum antivirals against viral fusion. Nat Rev Microbiol 13(7):426–437
pubmed: 26075364
pmcid: 4554337
doi: 10.1038/nrmicro3475
Chen Y, Cao L, Zhong M, Zhang Y, Han C, Li Q et al (2012) Anti-HIV-1 activity of a new scorpion venom peptide derivative Kn2-7. PLoS One 7(4):e34947. https://doi.org/10.1371/journal.pone.0034947
doi: 10.1371/journal.pone.0034947
pubmed: 22536342
pmcid: 3334916
Jenssen H, Hamill P, Hancock RE (2006) Peptide antimicrobial agents. Clin Microbiol Rev 19(3):491–511
pubmed: 16847082
pmcid: 1539102
doi: 10.1128/CMR.00056-05
Taguchi F, Shimazaki YK (2000) Functional analysis of an epitope in the S2 subunit of the murine coronavirus spike protein: involvement in fusion activity. J Gen Virol 81(12):2867–2871
pubmed: 11086117
doi: 10.1099/0022-1317-81-12-2867
Zhao H, Zhou J, Zhang K, Chu H, Liu D, Poon VKM et al (2016) A novel peptide with potent and broad-spectrum antiviral activities against multiple respiratory viruses. Sci Rep 6:22008. https://doi.org/10.1038/srep22008
doi: 10.1038/srep22008
pubmed: 26911565
pmcid: 4766503
Zumla A, Hui DS, Perlman S (2015) Middle East respiratory syndrome. Lancet 386(9997):995–1007
pubmed: 26049252
pmcid: 26049252
doi: 10.1016/S0140-6736(15)60454-8
de Wit E, van Doremalen N, Falzarano D, Munster VJ (2016) SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol 14(8):523–534
pubmed: 27344959
pmcid: 7097822
doi: 10.1038/nrmicro.2016.81
Li Q, Zhao Z, Zhou D, Chen Y, Hong W, Cao L et al (2011) Virucidal activity of a scorpion venom peptide variant mucroporin-M1 against measles, SARS-CoV and influenza H5N1 viruses. Peptides 32(7):1518–1525
pubmed: 21620914
pmcid: 7115635
doi: 10.1016/j.peptides.2011.05.015
Mustafa S, Balkhy H, Gabere M (2019) Peptide-protein interaction studies of antimicrobial peptides targeting middle east respiratory syndrome coronavirus spike protein: an in silico approach. Adv Bioinforma 2019:6815105. https://doi.org/10.1155/2019/6815105
doi: 10.1155/2019/6815105
Zhou N, Pan T, Zhang J, Li Q, Zhang X, Bai C et al (2016) Glycopeptide antibiotics potently inhibit cathepsin L in the late endosome/lysosome and block the entry of Ebola virus, Middle East respiratory syndrome coronavirus (MERS-CoV), and severe acute respiratory syndrome coronavirus (SARS-CoV). J Biol Chem 291(17):9218–9232
pubmed: 26953343
pmcid: 4861487
doi: 10.1074/jbc.M116.716100
Wohlford-Lenane CL, Meyerholz DK, Perlman S, Zhou H, Tran D, Selsted ME et al (2009) Rhesus theta-defensin prevents death in a mouse model of severe acute respiratory syndrome coronavirus pulmonary disease. J Virol 83(21):11385–11390
pubmed: 19710146
pmcid: 2772759
doi: 10.1128/JVI.01363-09
Padalko E, Nuyens D, De Palma A, Verbeken E, Aerts JL, De Clercq E et al (2004) The interferon inducer ampligen [poly (I)-poly (C12U)] markedly protects mice against coxsackie B3 virus-induced myocarditis. Antimicrob Agents Chemother 48(1):267–274
pubmed: 14693549
pmcid: 310159
doi: 10.1128/AAC.48.1.267-274.2004
Barnard DL, Kumaki Y (2011) Recent developments in anti-severe acute respiratory syndrome coronavirus chemotherapy. Future Virol 6(5):615–631
pubmed: 21765859
pmcid: 3136164
doi: 10.2217/fvl.11.33
Tong TR (2006) SARS coronavirus anti-infectives. Recent Pat Antiinfect Drug Discov 1(3):297–308
pubmed: 18221155
doi: 10.2174/157489106778777637
De Clercq E (2006) Interferon and its inducers–a never-ending story: “old” and “new” data in a new perspective. J Infect Dis 194(Suppl 1):S19–S26
pubmed: 16921467
pmcid: 7202558
doi: 10.1086/505351
Ershov F, Tazulakhova E (1999) Interferon inducers: new generation of immunomodulators. Vestn Ross Akad Med Nauk (4):52–56
Bao M, Zhang Y, Wan M, Dai L, Hu X, Wu X et al (2006) Anti-SARS-CoV immunity induced by a novel CpG oligodeoxynucleotide. Clin Immunol 118(2–3):180–187
pubmed: 16298165
doi: 10.1016/j.clim.2005.09.014
Barnard DL, Day CW, Bailey K, Heiner M, Montgomery R, Lauridsen L et al (2006) Evaluation of immunomodulators, interferons and known in vitro SARS-coV inhibitors for inhibition of SARS-coV replication in BALB/c mice. Antivir Chem Chemother 17(5):275–284
pubmed: 17176632
doi: 10.1177/095632020601700505
Kumaki Y, Day CW, Bailey KW, Wandersee MK, Wong MH, Madsen JR et al (2010) Induction of interferon-γ-inducible protein 10 by SARS-CoV infection, interferon alfacon 1 and interferon inducer in human bronchial epithelial Calu-3 cells and BALB/c mice. Antivir Chem Chemother 20(4):169–177
pubmed: 20231782
doi: 10.3851/IMP1477
Mojsoska B, Jenssen H (2015) Peptides and peptidomimetics for antimicrobial drug design. Pharmaceuticals 8(3):366–415
pubmed: 26184232
pmcid: 4588174
doi: 10.3390/ph8030366
Chuck C, Ke Z, Chen C, Wan D, Chow H, Wong K (2014) Profiling of substrate-specificity and rational design of broad-spectrum peptidomimetic inhibitors for main proteases of coronaviruses. Hong Kong Med J 20(Suppl 4):22–25
pubmed: 25224114
Ghosh AK, Xi K, Grum-Tokars V, Xu X, Ratia K, Fu W et al (2007) Structure-based design, synthesis, and biological evaluation of peptidomimetic SARS-CoV 3CLpro inhibitors. Bioorg Med Chem Lett 17(21):5876–5880
pubmed: 17855091
pmcid: 2112940
doi: 10.1016/j.bmcl.2007.08.031
Kumar V, Shin JS, Shie JJ, Ku KB, Kim C, Go YY et al (2017) Identification and evaluation of potent Middle East respiratory syndrome coronavirus (MERS-CoV) 3CLPro inhibitors. Antivir Res 141:101–106
pubmed: 28216367
doi: 10.1016/j.antiviral.2017.02.007
Kankanamalage ACG, Kim Y, Damalanka VC, Rathnayake AD, Fehr AR, Mehzabeen N et al (2018) Structure-guided design of potent and permeable inhibitors of MERS coronavirus 3CL protease that utilize a piperidine moiety as a novel design element. Eur J Med Chem 150:334–346
doi: 10.1016/j.ejmech.2018.03.004
Chuck CP, Chen C, Ke Z, Wan DCC, Chow HF, Wong KB (2013) Design, synthesis and crystallographic analysis of nitrile-based broad-spectrum peptidomimetic inhibitors for coronavirus 3C-like proteases. Eur J Med Chem 59:1–6
pubmed: 23202846
doi: 10.1016/j.ejmech.2012.10.053
Li SW, Wang CY, Jou YJ, Huang SH, Hsiao LH, Wan L et al (2016) SARS coronavirus papain-like protease inhibits the TLR7 signaling pathway through removing Lys63-linked polyubiquitination of TRAF3 and TRAF6. Int J Mol Sci 17(5):678. https://doi.org/10.3390/ijms17050678
doi: 10.3390/ijms17050678
pmcid: 4881504
pubmed: 4881504
Totura AL, Whitmore A, Agnihothram S, Schäfer A, Katze MG, Heise MT et al (2015) Toll-like receptor 3 signaling via TRIF contributes to a protective innate immune response to severe acute respiratory syndrome coronavirus infection. MBio 6(3):e00638–e00615
pubmed: 26015500
pmcid: 4447251
doi: 10.1128/mBio.00638-15
Zhao J, Wohlford-Lenane C, Zhao J, Fleming E, Lane TE, McCray PB et al (2012) Intranasal treatment with poly (I• C) protects aged mice from lethal respiratory virus infections. J Virol 86(21):11416–11424
pubmed: 22915814
pmcid: 3486278
doi: 10.1128/JVI.01410-12
Marston HD, Paules CI, Fauci AS (2017) The critical role of biomedical research in pandemic preparedness. JAMA 318(18):1757–1758
pubmed: 28979970
doi: 10.1001/jama.2017.15033
Bitko V, Barik S (2001) Phenotypic silencing of cytoplasmic genes using sequence-specific double-stranded short interfering RNA and its application in the reverse genetics of wild type negative-strand RNA viruses. BMC Microbiol 1(34):1–11
Deng T, Engelhardt OG, Thomas B, Akoulitchev AV, Brownlee GG, Fodor E (2006) Role of ran binding protein 5 in nuclear import and assembly of the influenza virus RNA polymerase complex. J Virol 80(24):11911–11919
pubmed: 17005651
pmcid: 1676300
doi: 10.1128/JVI.01565-06
Li T, Zhang Y, Fu L, Yu C, Li X, Li Y et al (2005) siRNA targeting the leader sequence of SARS-CoV inhibits virus replication. Gene Ther 12:751–761
pubmed: 15772689
pmcid: 7091583
doi: 10.1038/sj.gt.3302479
Chung YS, Kim MK, Lee WJ, Kang C (2007) Silencing E1A mRNA by RNA interference inhibits adenovirus replication. Arch Virol 152(7):1305–1314
pubmed: 17597352
pmcid: 7087230
doi: 10.1007/s00705-007-0951-z
Ge Q, Filip L, Bai A, Nguyen T, Eisen HN, Chen J (2004) Inhibition of influenza virus production in virus-infected mice by RNA interference. Proc Natl Acad Sci U S A 101(23):8676–8681
pubmed: 15173599
pmcid: 423254
doi: 10.1073/pnas.0402486101
Tompkins SM, Lo CY, Tumpey TM, Epstein SL (2004) Protection against lethal influenza virus challenge by RNA interference in vivo. Proc Natl Acad Sci U S A 101(23):8682–8686
pubmed: 15173583
pmcid: 423255
doi: 10.1073/pnas.0402630101
Zhou H, Jin M, Yu Z, Xu X, Peng Y, Wu H et al (2007) Effective small interfering RNAs targeting matrix and nucleocapsid protein gene inhibit influenza A virus replication in cells and mice. Antivir Res 76(2):186–193
pubmed: 17719657
doi: 10.1016/j.antiviral.2007.07.002
Li BJ, Tang Q, Cheng D, Qin C, Xie FY, Wei Q et al (2005) Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in rhesus macaque. Nat Med 11(9):944–951
pubmed: 16116432
pmcid: 7095788
doi: 10.1038/nm1280
Millet JK, Whittaker GR (2014) Host cell entry of Middle East respiratory syndrome coronavirus after two-step, furin-mediated activation of the spike protein. Proc Natl Acad Sci U S A 111(42):15214–15152
pubmed: 25288733
pmcid: 4210292
doi: 10.1073/pnas.1407087111
Wu CJ, Huang HW, Liu CY, Hong CF, Chan YL (2005) Inhibition of SARS-CoV replication by siRNA. Antivir Res 65(1):45–48
Sheikhshahrokh A, Ranjbar R, Saeidi E, DEHKORDI FS, Heiat M, Ghasemi-Dehkordi P et al (2020) Frontier therapeutics and vaccine strategies for sars-cov-2 (COVID-19): A review. Iran J Public Health 49:18–29
Heiat M, Hashemi-Aghdam MR, Heiat F, Rastegar Shariat Panahi M, Aghamollaei H, Moosazadeh Moghaddam M et al (2020) Integrative role of traditional and modern technologies to combat COVID-19. Expert Rev Anti Infect Ther 19:1–1
Mirzaie A, Halaji M, Dehkordi FS, Ranjbar R, Noorbazargan H (2020) A narrative literature review on traditional medicine options for treatment of corona virus disease 2019 (COVID-19). Complement Ther Clin Pract 17:101214